[PharmaEssentia] Announcement of significant resolutions from the 2026 annual general meeting (acting by the Board) of major subsidiary FanTai Medical Products Co., Ltd.
NQ Score
0/100
N1 Content Completeness
5
AI Summary (NQ-processed)
PharmaEssentia's major subsidiary, FanTai Medical Products Co., Ltd., held its 2026 annual general meeting, approving the 2025 financial report and the loss recovery plan.